A Strategy to Treat COVID‐19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a newly identified pathogen causing the coronavirus disease 2019 (COVID‐19) pandemic. Hydroxychloroquine (HCQ), an antimalarial and anti‐inflammatory drug, has been shown to inhibit SARS‐CoV‐2 infection in vitro and tested in clinical s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tai, Tien‐Tzu, Wu, Tzung‐Ju, Wu, Huey‐Dong, Tsai, Yi‐Chen, Wang, Hui‐Ting, Wang, An‐Min, Shih, Sheue‐Fang, Chen, Yee‐Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877818/
https://www.ncbi.nlm.nih.gov/pubmed/33135382
http://dx.doi.org/10.1111/cts.12923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877818/
https://www.ncbi.nlm.nih.gov/pubmed/33135382
http://dx.doi.org/10.1111/cts.12923

Ejemplares similares